You are here: Home > Why We Exist > What We Support > Grants
2013 Grants
Cookies for Kids' Cancer provides annual research grants to five leading pediatric cancer centers, including St. Jude Children's Research Hospital, Dana Farber Cancer Institute, Texas Children's Cancer Center and Memorial Sloan-Kettering Cancer Center. Our focus is on advancing the development of less toxic, more effective treatments for children with cancer.

Our medical advisory board carefully reviews each grant request, and provides their recommendations of the projects most likely to result in promising treatments advancing to clinical trial as quickly as possible, where they can begin helping children fighting cancer. 

This year, we are proud to announce grants totaling $1.5 million, bringing our total amount granted to $5 million in just a few short years. 

A portion of funds raised also matches the federal government allowance for every child enrolled in a phase 1 clinical trial in the Children's Oncology Group's Phase I Trial Consortium. Currently, there are 21 hospitals nationwide within this group.

Grant Recipients:
Institution Overview
Children's Hospital of Philadelphia Novel cell-based therapy for B-Cell Leukemias and Lymphomas
Children's Hospital of Philadelphia Decreasing resistance to chemotherapies in pediatric Lymphomas, as well as decreasing sensitivities and effects related to the harsh chemotherapy drug Doxorubicin
Texas Children's Hospital Phase 1 study for children with refractory or recurrent solid tumors
Dana Farber Cancer Institute Developing new treatments for Neuroblastoma by targeting the disease's Epigenome
Memorial Sloan-Kettering Cancer Center Retargeting T-Cells using Bispecific Antibody to address and overcome pain and other issues seen with pediatric sold tumor treatments
Children's Oncology Group 3-year nationwide study to standardize surgical treatment for pulmonary metastasis in Osteosarcomas.
St. Jude Children's Research Hospital Study to gain understanding of phenotypic Leukemias, and whether these diseases are genetically heterogeneous gaining first real insight into the condition
Texas Children's Hospital Phase 1 Clinical Trial: Using immunotherapy treatment as an alternative to toxic chemotherapy treatments. Immunotherapy is believed to build up natural antitumor properties with limited toxicity.


Follow us on Facebook and Twitter, and sign up for our E-newsletterfor exclusive updates!


Be a Good Cookie.™
Let's make the letter C mean cookies l cookiesforkidscancer.org

Cookies for Kids' Cancer is an IRS recognized 501(c)3 non-profit. Your donation or purchase is tax deductible.